A Phase 3 interventional study of Influsplit™ Tetra (Fluarix™ Tetra) and Pneumovax™ 23 in Influenza, sponsored by GlaxoSmithKline. Completed at 6 sites in 2 countries. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-04-03.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies in Influenza, Human by GlaxoSmithKline — 3 open to participants now, 3 under way, 2 of them phase 3. Influenza, Human · GlaxoSmithKline.
Among the 187 studies in Influenza, Human by GlaxoSmithKline, this one is the 80th largest by enrollment of the 165 interventional ones that give a count, is one of 4 that started in 2014, is one of 74 in phase 3, and was the 161st registered.
2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.
Browse Influenza, Human studies →3 of the 187 studies in Influenza, Human by GlaxoSmithKline are open now, in 1 country. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States
Ages 18–64 · Healthy volunteers
GlaxoSmithKline · Sites in United States
Ages 65+ · Healthy volunteers
GlaxoSmithKline · Sites in United States
Ages 65–85
By country, each count listing its studies:
Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 56 · Phase 3 74 · Phase 4 12
First in 2002; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 357 is above the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 324 across the 165 interventional studies, 605 across the 22 observational. Of the 178 that completed or were terminated, 132 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
2 of the studies in Influenza, Human by GlaxoSmithKline that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07851246Phase 3GlaxoSmithKlineA Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age | 2027-07-09 |
| NCT07464314GlaxoSmithKlineA Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults | 2026-12-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 187 studies in Influenza, Human by GlaxoSmithKline, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate the immunogenicity and safety when GSK Biologicals' influenza vaccine Influsplit™ Tetra (Fluarix™ Tetra) is co-administered with Merck \& Co. Inc.'s pneumococcal vaccine (Pneumovax™23/Pneumovax) in adults 50 years of age and older at risk for complications from influenza and pneumococcal infections.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A male or female aged 50 years or above at the time of the first vaccination at risk for complications from influenza and/or pneumococcal infections, meeting their respective countries' recommendations for vaccination against influenza and pneumococcal disease.
Female subjects of non- may be enrolled in the study.
Female subjects of childbearing potential may be enrolled in the study, if the subject:
Exclusion Criteria:
Administration of long-acting immune-modifying drugs/treatment within six months prior to the first vaccine dose or expected administration at any time during the study period. These immunosuppressant drugs/treatment/Biologics include:
Acute disease and/or fever at the time of enrolment.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received 1 dose of Influsplit™ Tetra vaccine and 1 dose of Pneumovax™ 23 vaccine at Day 0 and 1 dose of placebo at Day 28.
Biological: Influsplit™ Tetra (Fluarix™ Tetra) · Biological: Pneumovax™ 23 · Biological: Placebo (Saline)
Subjects received 1 dose of Influsplit™ Tetra vaccine and 1 dose of placebo at Day 0 and 1 dose of Pneumovax™ 23 vaccine at Day 28.
Biological: Influsplit™ Tetra (Fluarix™ Tetra) · Biological: Pneumovax™ 23 · Biological: Placebo (Saline)
Intramuscular injection, 1 dose each in Control and Co-Ad groups.
Also known as: D-QIV, GSK2321138A
Drug page: 23-valent pneumococcal capsular polysaccharide vaccine
Intramuscular injection, 1 dose each in Control and Co-Ad groups.
Intramuscular injection, 1 dose each in Control and Co-Ad groups.
Humoral Immune Response in Terms of Haemagglutination Inhibition (HI) Antibodies Titers Against the 4 Vaccine Strains.
HI antibody titres were expressed as geometric mean titers (GMTs) and adjusted GMT ratios (Control Group/Co-Ad Group). The vaccine strains assessed were Flu A/Christchurch/16/2010 (H1N1), FluA/Texas/50/2012 (H3N2), Flu B/Brisbane/60/2008 (Victoria) and Flu B/Massachusetts/2/2012 (Yamagata).
Time frame: At Day 28 post Influsplit™ Tetra vaccination
Pneumococcal Vaccine Response in Terms of Anti-pneumococcal Antibody Concentrations Against 6 Pneumococcal Serotypes (1, 3, 4, 7F, 14 and 19A).
Anti-pneumococcal antibody concentrations were expressed as adjusted geometric mean concentrations (GMCs) and adjusted GMC ratio (Control Group/Co-Ad Group).
Time frame: At 28 days after Pneumovax™ 23 vaccination
Number of Subjects Reporting Solicited Local Adverse Events (AEs)
Solicited local symptoms assessed were pain, redness and swelling. Any = occurrence of the specified solicited local symptom regardless of its intensity. Grade 3 pain = significant pain at rest and pain that prevented normal everyday activities. Grade 3 redness and swelling = greater than 50 millimeters (mm) i.e. \> 100mm.
Time frame: Within 7 days (Days 0 - 6) after each dose and across doses.
Number of Subjects Reporting Solicited General Adverse Events (AEs)
Solicited general symptoms assessed were fatigue, gastrointestinal symptoms\*, headache, joint pain, muscle aches, shivering, sweating and fever. Any was defined as any solicited general symptom reported irrespective of intensity and relationship to vaccination. Grade 3 was defined as symptoms that prevented normal everyday activities. Related was defined as symptoms assessed by the investigator to have a causal relationship to vaccination. Grade 3 fever was defined as temperature greater than (\>)39.0°C. \*Gastrointestinal (GI) symptoms included nausea, vomiting, diarrhoea and/or abdominal pain
Time frame: Within 7 days (Days 0 - 6) after each dose and across doses.
Duration of Local Adverse Events
Duration was defined as number of days with any grade of local symptoms.
Time frame: During the 7-day (Days 0-6) post-vaccination period
Duration of Solicited General AEs.
Duration was defined as number of days with any grade of general symptoms.
Time frame: During the 7-day (Days 0-6) post-vaccination period
Number of Subjects Reporting the Occurrence of Medically Attended Adverse Events (MAEs)
MAEs were defined as adverse events with medically-attended visits that were not routine visits for physical examination or vaccination, such as visits for hospitalization, an emergency room visit, or an otherwise unscheduled visit to or from medical personnel (medical doctor) for any reason. Any was defined as any occurrence of MAE(s) regardless of intensity grade or relationship to vaccination. Related was defined as MAE assessed by the investigator to be causally related to the study vaccination.
Time frame: Throughout the study period (Days 0-180)
Number of Subjects Reporting the Occurrence of Potential Immune Mediated Diseases (pIMDs)
Potential immune-mediated diseases (pIMDs) were defined as a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Any was defined as any occurrence of pIMD(s) regardless of intensity grade or relationship to vaccination. Related was defined as pIMD assessed by the investigator to be causally related to the study vaccination.
Time frame: During the entire study period (Days 0-180)
Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs).
An unsolicited AE was defined as an untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination.
Time frame: Within the 28-day (Days 0-27) post-vaccination period
Number of Subjects Reporting Serious Adverse Events (SAEs)
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.
Time frame: Throughout the study period (Days 0-180)
Humoral Immune Response in Terms of Haemagglutination Inhibition (HI) Antibodies in Subjects by Calculating Serum Antihaemagglutination (HA) Antibody Titers Against the 4 Influenza Vaccine Strains
HI antibody titres were expressed as Geometric mean titers (GMTs). The vaccine strains assessed were Flu A/Christchurch/16/2010 (H1N1), Flu A/Texas/50/2012 (H3N2), Flu B/Brisbane/60/2008 (Victoria) and Flu B/Massachusetts/02/2012 (Yamagata).
Time frame: At Day 0 and Day 28
Number of Subjects Who Were Seroprotected for Haemagglutination Inhibition (HI) Antibodies Against Each of the Four Vaccine Influenza Strains.
A seroprotected subject was defined as a vaccinated subject with a serum HI titer greater than or equal to (≥) 1:40 that usually is accepted as indicating protection in adults. The vaccine strains assessed were Flu A/Christchurch/16/2010 (H1N1), Flu A/Texas/50/2012 (H3N2), Flu B/Brisbane/60/2008 (Victoria) and Flu B/Massachusetts/2/2012 (Yamagata).
Time frame: At Day 0 and Day 28
Number of Seroconverted Subjects for Anti-Haemagglutination Inhibition (HI) Antibodies Against Each of the Four Vaccine Influenza Strains.
A seroconverted subject was defined as a vaccinated subject with either a pre-vaccination titer less than (\<) 1:10 and a post-vaccination titer greater than or equal to (≥) 1:40, or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains assessed were Flu A/Christchurch/16/2010 (H1N1), Flu A/Texas/50/2012 (H3N2), Flu B/Brisbane/60/2008 (Victoria) and Flu B/Massachusetts/02/2012 (Yamagata).
Time frame: At Day 28
Mean Geometric Increase (MGI) for Haemagglutination Inhibition (HI) Antibody Titer Against Each of the Four Vaccine Influenza Strains.
MGI was defined as the fold increase in serum haemagglutination inhibition (HI) GMTs post-vaccination compared to pre-vaccination (Day 0). The vaccine strains assessed were Flu A/Christchurch/16/2010 (H1N1), Flu A/Texas/50/2012 (H3N2), Flu B/Brisbane/60/2008 (Victoria) and Flu B/Massachusetts/02/2012 (Yamagata).
Time frame: At Day 28
Number of Subjects With Anti-pneumococcal Antibody Concentrations for the Following Serotypes: 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F
The pneumococcal antigen testing was performed, as determined by ELISA cut-offs of ≥0.05 µg/mL and a seroprotection cut-off of ≥ 0.2 µg/ml. PRE = Pre-vaccination i.e. at Day 0 for Co-Ad Group and at Day 28 for Control Group. POST = Post-vaccination i.e. at Day 28 for Co-Ad Group and at Day 56 for Control Group.
Time frame: At Days 0 (Co-Ad group only), 28 (both groups), and 56 (Control group only)
Pneumococcal Vaccine Response in Terms of Anti-pneumococcal Antibody Concentrations Against 12 Pneumococcal Serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F)
Anti-pneumococcal antibody concentrations were expressed as adjusted geometric mean concentrations (GMCs) PRE = Pre -vaccination i.e. at Day 0 for Co-Ad Group and at Day 28 for Control Group. POST = Post-vaccination i.e. at Day 28 for Co-Ad Group and at Day 56 for Control Group.
Time frame: At Days 0 (Co-Ad group only), 28 (both groups), and 56 (Control group only)
Number of Subjects Whose N Antibody Titers Were at Least 2 or 4-fold Higher Than Their Pre-vaccination Titer by Anti-pneumococcal Serotype Subjects.
Fold antibody concentration increases post-vaccination/pre-vaccination ≥ 2 and ≥ 4. The anti-pneumococcal serotypes assessed were 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.
Time frame: At 28 days post-vaccination with Pneumovax™ 23
In the Control Group, 2 subjects withdrew at Day 0. In the Co-Ad Group, 4 subjects withdrew at Day 0, 1 subject withdrew at Day 28 and 1 subject withdrew at Day 56.
| Milestone | Control Group | Co-Ad Group |
|---|---|---|
| Started | 179 | 177 |
| Completed | 177 | 171 |
| Not completed | 2 | 6 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Unwilling to be vaccinated in left arm | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 3 |
HI antibody titres were expressed as geometric mean titers (GMTs) and adjusted GMT ratios (Control Group/Co-Ad Group). The vaccine strains assessed were Flu A/Christchurch/16/2010 (H1N1), FluA/Texas/50/2012 (H3N2), Flu B/Brisbane/60/2008 (Victoria) and Flu B/Massachusetts/2/2012 (Yamagata).
| Titers | Control Group | Co-Ad Group |
|---|---|---|
| H1N1 | 253.2 (205.3 to 312.1) | 235.5 (195.0 to 284.5) |
| H3N2 | 73.6 (62.1 to 87.1) | 78.6 (65.2 to 94.7) |
| Victoria | 178.7 (154.9 to 206.2) | 157.9 (136.4 to 182.9) |
| Yamagata | 346.5 (302.3 to 397.1) | 353.8 (310.5 to 403.2) |
Anti-pneumococcal antibody concentrations were expressed as adjusted geometric mean concentrations (GMCs) and adjusted GMC ratio (Control Group/Co-Ad Group).
| ug per ml | Control Group | Co-Ad Group |
|---|---|---|
| Polysaccharide 01 IgG | 5.5 (4.3 to 7.0) | 4.9 (3.9 to 6.2) |
| Polysaccharide 03 IgG | 1.7 (1.4 to 2.1) | 1.7 (1.4 to 2.0) |
| Polysaccharide 04 IgG | 2.3 (1.8 to 2.9) | 1.7 (1.4 to 2.2) |
| Polysaccharide 7F IgG | 9.0 (6.9 to 11.8) | 8.1 (6.2 to 10.6) |
| Polysaccharide 14 IgG | 20.2 (16.0 to 25.6) | 14.1 (11.3 to 17.6) |
| Polysaccharide 19A IgG | 9.2 (7.1 to 11.9) | 7.7 (6.1 to 9.8) |
Solicited local symptoms assessed were pain, redness and swelling. Any = occurrence of the specified solicited local symptom regardless of its intensity. Grade 3 pain = significant pain at rest and pain that prevented normal everyday activities. Grade 3 redness and swelling = greater than 50 millimeters (mm) i.e. \> 100mm.
| Subjects | Control Group | Co-Ad Group |
|---|---|---|
| Any Pain, Dose 1 (Influsplit™ Tetra) | 28 | 58 |
| Grade 3 Pain,Dose 1(Influsplit™ Tetra) | 0 | 2 |
| Any Pain, Dose 1 (Placebo) | 10 | — |
| Grade 3 Pain, Dose 1 (Placebo) | 0 | — |
| Any Pain, Dose 1 (Pneumovax™ 23) | — | 76 |
| Grade 3 Pain, Dose 1 (Pneumovax™ 23) | — | 6 |
| Any Redness, Dose 1 (Influsplit™ Tetra) | 3 | 2 |
| Grade3 Redness,Dose 1(Influsplit™ Tetra) | 0 | 0 |
| Any Redness, Dose 1 (Placebo) | 3 | — |
| Grade 3 Redness, Dose 1 (Placebo) | 0 | — |
| Any Redness, Dose 1 (Pneumovax™ 23) | — | 8 |
| Grade 3 Redness, Dose 1 (Pneumovax™ 23) | — | 0 |
| Any Swelling, Dose1 (Influsplit™ Tetra) | 1 | 3 |
| Grade3 Swelling,Dose1(Influsplit™ Tetra) | 0 | 0 |
| Any Swelling, Dose 1 (Placebo) | 1 | — |
| Grade 3 Swelling, Dose 1 (Placebo) | 0 | — |
| Any Swelling, Dose 1 (Pneumovax™ 23) | — | 7 |
| Grade 3 Swelling,Dose 1 (Pneumovax™ 23) | — | 0 |
| Any Pain, Dose 2 (Placebo) | — | 8 |
| Grade 3 Pain, Dose 2 (Placebo) | — | 0 |
| Any Pain, Dose 2 (Pneumovax™ 23) | 63 | — |
| Grade 3 Pain, Dose 2 (Pneumovax™ 23) | 8 | — |
| Any Redness, Dose 2 (Placebo) | — | 1 |
| Grade 3 Redness, Dose 2 (Placebo) | — | 0 |
| Any Redness, Dose 2 (Pneumovax™ 23) | 8 | — |
| Grade 3 Redness, Dose 2 (Pneumovax™ 23) | 1 | — |
| Any Swelling, Dose 2 (Placebo) | — | 0 |
| Grade 3 Swelling, Dose 2 (Placebo) | — | 0 |
| Any Swelling, Dose 2 (Pneumovax™ 23) | 5 | — |
| Grade 3 Swelling, Dose 2 (Pneumovax™ 23) | 1 | — |
| Any Pain, Across Doses (Influsplit™ Tetra) | 28 | 58 |
| Grade 3 Pain, Across Doses (Influsplit™Tetra) | 0 | 2 |
| Any Pain, Across Doses (Placebo) | 10 | 8 |
| Grade 3 Pain, Across Doses (Placebo) | 0 | 0 |
| Any Pain, Across Doses (Pneumovax™ 23) | 63 | 76 |
| Grade 3 Pain, Across Doses (Pneumovax™ 23) | 8 | 6 |
| Any Redness, Across Doses (Influsplit™Tetra) | 3 | 2 |
| Grade 3 Redness, Across Doses (Influsplit™ Tetra) | 0 | 0 |
| Any Redness, Across Doses (Placebo) | 3 | 1 |
| Grade 3 Redness, Across Doses (Placebo) | 0 | 0 |
| Any Redness, Across Doses (Pneumovax™ 23) | 8 | 8 |
| Grade 3 Redness, Across Doses (Pneumovax™23) | 1 | 0 |
| Any Swelling, Across Doses (Influsplit™Tetra) | 1 | 3 |
| Grade 3 Swelling, Across Doses (Influsplit™Tetra) | 0 | 0 |
| Any Swelling, Across Doses (Placebo) | 1 | 0 |
| Grade 3 Swelling, Across Doses (Placebo) | 0 | 0 |
| Any Swelling, Across Doses (Pneumovax™23) | 5 | 7 |
| Grade 3 Swelling, Across Doses (Pneumovax™23) | 1 | 0 |
Solicited general symptoms assessed were fatigue, gastrointestinal symptoms\*, headache, joint pain, muscle aches, shivering, sweating and fever. Any was defined as any solicited general symptom reported irrespective of intensity and relationship to vaccination. Grade 3 was defined as symptoms that prevented normal everyday activities. Related was defined as symptoms assessed by the investigator to have a causal relationship to vaccination. Grade 3 fever was defined as temperature greater than (\>)39.0°C. \*Gastrointestinal (GI) symptoms included nausea, vomiting, diarrhoea and/or abdominal pain
| Subjects | Control Group | Co-Ad Group |
|---|---|---|
| Any Fatigue, Dose 1 | 30 | 39 |
| Grade 3 Fatigue, Dose 1 | 1 | 2 |
| Related Fatigue, Dose 1 | 23 | 33 |
| Any GI symptoms, Dose 1 | 16 | 12 |
| Grade 3 GI symptoms, Dose 1 | 1 | 1 |
| Related GI symptoms, Dose 1 | 9 | 5 |
| Any Headache, Dose 1 | 21 | 20 |
| Grade 3 Headache, Dose 1 | 0 | 2 |
| Related Headache, Dose 1 | 13 | 17 |
| Any Joint pain, Dose 1 | 11 | 16 |
| Grade 3 Joint pain, Dose 1 | 0 | 0 |
| Related Joint pain, Dose 1 | 6 | 14 |
| Any Muscle aches, Dose 1 | 15 | 20 |
| Grade 3 Muscle aches, Dose 1 | 0 | 1 |
| Related Muscle aches, Dose 1 | 12 | 19 |
| Any Shivering, Dose 1 | 6 | 10 |
| Grade 3 Shivering, Dose 1 | 0 | 1 |
| Related Shivering, Dose 1 | 5 | 8 |
| Any Sweating, Dose 1 | 11 | 16 |
| Grade 3 Sweating, Dose 1 | 0 | 1 |
| Related Sweating, Dose 1 | 9 | 10 |
| Any Fever, Dose 1 | 0 | 2 |
| Grade 3 Fever, Dose 1 | 0 | 1 |
| Related Fever, Dose 1 | 0 | 2 |
| Any Fatigue, Dose 2 | 25 | 12 |
| Grade 3 Fatigue, Dose 2 | 1 | 0 |
| Related Fatigue, Dose 2 | 22 | 6 |
| Any GI symptoms, Dose 2 | 11 | 7 |
| Grade 3 GI symptoms, Dose 2 | 0 | 1 |
| Related GI symptoms, Dose 2 | 9 | 2 |
| Any Headache, Dose 2 | 18 | 10 |
| Grade 3 Headache, Dose 2 | 1 | 0 |
| Related Headache, Dose 2 | 14 | 3 |
| Any Joint pain, Dose 2 | 17 | 11 |
| Grade 3 Joint pain, Dose 2 | 1 | 0 |
| Related Joint pain, Dose 2 | 12 | 7 |
| Any Muscle aches, Dose 2 | 21 | 12 |
| Grade 3 Muscle aches, Dose 2 | 4 | 0 |
| Related Muscle aches, Dose 2 | 19 | 6 |
| Any Shivering, Dose 2 | 8 | 5 |
| Grade 3 Shivering, Dose 2 | 1 | 0 |
| Related Shivering, Dose 2 | 5 | 3 |
| Any Sweating, Dose 2 | 10 | 8 |
| Grade 3 Sweating, Dose 2 | 1 | 0 |
| Related Sweating, Dose 2 | 5 | 5 |
| Any Fever, Dose 2 | 1 | 0 |
| Grade 3 Fever, Dose 2 | 0 | 0 |
| Related Fever, Dose 2 | 1 | 0 |
| Any Fatigue, Across Doses | 43 | 43 |
| Grade 3 Fatigue, Across Doses | 2 | 2 |
| Related Fatigue, Across Doses | 34 | 37 |
| Any GI symptoms, Across Doses | 23 | 17 |
| Grade 3 GI symptoms, Across Doses | 1 | 2 |
| Related GI symptoms, Across Doses | 15 | 7 |
| Any Headache, Across Doses | 30 | 27 |
| Grade 3 Headache, Across Doses | 1 | 2 |
| Related Headache, Across Doses | 22 | 20 |
| Any Joint pain, Across Doses | 25 | 23 |
| Grade 3 Joint pain, Across Doses | 1 | 0 |
| Related Joint pain, Across Doses | 16 | 20 |
| Any Muscle aches, Across Doses | 32 | 28 |
| Grade 3 Muscle aches, Across Doses | 4 | 1 |
| Related Muscle aches, Across Doses | 28 | 24 |
| Any Shivering, Across Doses | 13 | 14 |
| Grade 3 Shivering, Across Doses | 1 | 1 |
| Related Shivering, Across Doses | 9 | 10 |
| Any Sweating, Across Doses | 16 | 19 |
| Grade 3 Sweating, Across Doses | 1 | 1 |
| Related Sweating, Across Doses | 11 | 14 |
| Any Fever, Across Doses | 1 | 2 |
| Grade 3 Fever, Across Doses | 0 | 1 |
| Related Fever, Across Doses | 1 | 2 |
Duration was defined as number of days with any grade of local symptoms.
| Days | Control Group | Co-Ad Group |
|---|---|---|
| Pain, Dose 1 | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 3.0) |
| Pain, Dose 2 | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 3.0) |
| Redness, Dose 1 | 4.0 (3.0 to 4.0) | 2.0 (2.0 to 3.0) |
| Redness, Dose 2 | 2.0 (1.0 to 2.5) | 1.0 (1.0 to 1.0) |
| Swelling, Dose 1 | 4.5 (4.0 to 5.0) | 2.0 (2.0 to 4.0) |
| Swelling, Dose 2 | 3.0 (1.0 to 5.0) | — |
Duration was defined as number of days with any grade of general symptoms.
| Days | Control Group | Co-Ad Group |
|---|---|---|
| Fatigue, Dose 1 | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 3.0) |
| Fatigue, Dose 2 | 3.0 (2.0 to 4.0) | 3.5 (1.5 to 6.5) |
| Gastrointestinal symptoms, Dose 1 | 2.0 (1.0 to 4.0) | 2.0 (1.0 to 2.0) |
| Gastrointestinal symptoms, Dose 2 | 3.0 (2.0 to 3.0) | 3.0 (2.0 to 6.0) |
| Headache, Dose 1 | 1.0 (1.0 to 2.0) | 1.5 (1.0 to 2.5) |
| Headache, Dose 2 | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 3.0) |
| Joint pain, Dose 1 | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 4.0) |
| Joint pain, Dose 2 | 2.0 (2.0 to 3.0) | 2.0 (1.0 to 7.0) |
| Muscle aches, Dose 1 | 2.0 (1.0 to 3.0) | 3.0 (1.5 to 4.5) |
| Muscle aches, Dose 2 | 2.0 (1.0 to 3.0) | 2.0 (1.0 to 4.0) |
| Sweating, Dose 1 | 2.0 (1.0 to 6.0) | 2.0 (1.0 to 3.5) |
| Sweating, Dose 2 | 2.0 (1.0 to 5.0) | 2.0 (1.5 to 2.0) |
| Shivering, Dose 1 | 2.0 (1.0 to 2.0) | 1.0 (1.0 to 2.0) |
| Shivering, Dose 2 | 1.0 (1.0 to 2.0) | 3.0 (1.0 to 3.0) |
| Fever, Dose 1 | — | 1.0 (1.0 to 1.0) |
| Fever, Dose 2 | 1.0 (1.0 to 1.0) | — |
MAEs were defined as adverse events with medically-attended visits that were not routine visits for physical examination or vaccination, such as visits for hospitalization, an emergency room visit, or an otherwise unscheduled visit to or from medical personnel (medical doctor) for any reason. Any was defined as any occurrence of MAE(s) regardless of intensity grade or relationship to vaccination. Related was defined as MAE assessed by the investigator to be causally related to the study vaccination.
| Subjects | Control Group | Co-Ad Group |
|---|---|---|
| Any MAE(s) | 37 | 43 |
| Related MAE(s) | 2 | 2 |
Potential immune-mediated diseases (pIMDs) were defined as a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Any was defined as any occurrence of pIMD(s) regardless of intensity grade or relationship to vaccination. Related was defined as pIMD assessed by the investigator to be causally related to the study vaccination.
| Subjects | Control Group | Co-Ad Group |
|---|---|---|
| Any pIMD(s) | 0 | 1 |
| Related pIMD(s) | 0 | 0 |
An unsolicited AE was defined as an untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination.
| Subjects | Control Group | Co-Ad Group |
|---|---|---|
| Any Unsolicited AEs | 35 | 42 |
| Grade 3 Unsolicited AEs | 5 | 8 |
| Related Unsolicited AEs | 5 | 5 |
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination and related was an event assessed by the investigator as causally related to the study vaccination.
| Subjects | Control Group | Co-Ad Group |
|---|---|---|
| Any SAE(s) | 11 | 7 |
| Related SAE(s) | 0 | 0 |
| Fatal SAE(s) | 0 | 1 |
| Related Fatal SAE(s) | 0 | 0 |
HI antibody titres were expressed as Geometric mean titers (GMTs). The vaccine strains assessed were Flu A/Christchurch/16/2010 (H1N1), Flu A/Texas/50/2012 (H3N2), Flu B/Brisbane/60/2008 (Victoria) and Flu B/Massachusetts/02/2012 (Yamagata).
| Titers | Control Group | Co-Ad Group |
|---|---|---|
| H1N1, Day 0 | 32.4 (26.3 to 39.9) | 253.2 (205.3 to 312.1) |
| H1N1, Day 28 | 34.0 (27.8 to 41.7) | 235.5 (195.0 to 284.5) |
| H3N2, Day 0 | 20.8 (17.5 to 24.9) | 21.8 (18.2 to 26.2) |
| H3N2, Day 28 | 73.6 (62.1 to 87.1) | 78.6 (65.2 to 94.7) |
| Victoria, Day 0 | 48.7 (41.6 to 57.1) | 51.5 (43.9 to 60.3) |
| Victoria, Day 28 | 178.7 (154.9 to 206.2) | 157.9 (136.4 to 182.9) |
| Yamagata, Day 0 | 120.7 (104.3 to 139.8) | 119.9 (103.0 to 139.5) |
| Yamagata, Day 28 | 346.5 (302.3 to 397.1) | 353.8 (310.5 to 403.2) |
A seroprotected subject was defined as a vaccinated subject with a serum HI titer greater than or equal to (≥) 1:40 that usually is accepted as indicating protection in adults. The vaccine strains assessed were Flu A/Christchurch/16/2010 (H1N1), Flu A/Texas/50/2012 (H3N2), Flu B/Brisbane/60/2008 (Victoria) and Flu B/Massachusetts/2/2012 (Yamagata).
| Subjects | Control Group | Co-Ad Group |
|---|---|---|
| H1N1, Day 0 | 83 | 77 |
| H1N1, Day 28 | 160 | 157 |
| H3N2, Day 0 | 57 | 50 |
| H3N2, Day 28 | 131 | 128 |
| Victoria, Day 0 | 106 | 113 |
| Victoria, Day 28 | 167 | 154 |
| Yamagata, Day 0 | 159 | 146 |
| Yamagata, Day 28 | 169 | 162 |
A seroconverted subject was defined as a vaccinated subject with either a pre-vaccination titer less than (\<) 1:10 and a post-vaccination titer greater than or equal to (≥) 1:40, or a pre-vaccination titer ≥ 1:10 and at least a 4-fold increase in post-vaccination titer. The vaccine strains assessed were Flu A/Christchurch/16/2010 (H1N1), Flu A/Texas/50/2012 (H3N2), Flu B/Brisbane/60/2008 (Victoria) and Flu B/Massachusetts/02/2012 (Yamagata).
| Subjects | Control Group | Co-Ad Group |
|---|---|---|
| H1N1 | 110 | 101 |
| H3N2 | 62 | 61 |
| Victoria | 73 | 55 |
| Yamagata | 60 | 54 |
MGI was defined as the fold increase in serum haemagglutination inhibition (HI) GMTs post-vaccination compared to pre-vaccination (Day 0). The vaccine strains assessed were Flu A/Christchurch/16/2010 (H1N1), Flu A/Texas/50/2012 (H3N2), Flu B/Brisbane/60/2008 (Victoria) and Flu B/Massachusetts/02/2012 (Yamagata).
| Fold increase | Control Group | Co-Ad Group |
|---|---|---|
| H1N1 | 7.7 (6.1 to 9.7) | 6.9 (5.5 to 8.6) |
| H3N2 | 3.5 (3.0 to 4.2) | 3.6 (3.0 to 4.4) |
| Victoria | 3.6 (3.1 to 4.3) | 3.1 (2.6 to 3.6) |
| Yamagata | 2.8 (2.5 to 3.3) | 3.0 (2.5 to 3.4) |
The pneumococcal antigen testing was performed, as determined by ELISA cut-offs of ≥0.05 µg/mL and a seroprotection cut-off of ≥ 0.2 µg/ml. PRE = Pre-vaccination i.e. at Day 0 for Co-Ad Group and at Day 28 for Control Group. POST = Post-vaccination i.e. at Day 28 for Co-Ad Group and at Day 56 for Control Group.
| Subjects | Control Group | Co-Ad Group |
|---|---|---|
| Polysaccharide 01 Ab.IgG (≥ 0.05 µg/ml) (PRE) | 162 | 152 |
| Polysaccharide 01 Ab.IgG (≥ 0.05 µg/ml) (POST) | 169 | 162 |
| Polysaccharide 01 Ab.IgG (≥ 0.2 µg/ml) (PRE) | 112 | 118 |
| Polysaccharide 01 Ab.IgG (≥ 0.2 µg/ml) (POST) | 167 | 159 |
| Polysaccharide 03 Ab.IgG (≥ 0.05 µg/ml) (PRE) | 158 | 149 |
| Polysaccharide 03 Ab.IgG (≥ 0.05 µg/ml) (POST) | 167 | 161 |
| Polysaccharide 03 Ab.IgG (≥ 0.2 µg/ml) (PRE) | 114 | 121 |
| Polysaccharide 03 Ab.IgG (≥ 0.2 µg/ml) (POST) | 158 | 153 |
| Polysaccharide 04 Ab.IgG (≥ 0.05 µg/ml) (PRE) | 138 | 129 |
| Polysaccharide 04 Ab.IgG (≥ 0.05 µg/ml) (POST) | 167 | 158 |
| Polysaccharide 04 Ab.IgG (≥ 0.2 µg/ml) (PRE) | 77 | 82 |
| Polysaccharide 04 Ab.IgG (≥ 0.2 µg/ml) (POST) | 158 | 149 |
| Polysaccharide 05 Ab.IgG5 (≥ 0.05 µg/ml) (PRE) | 165 | 159 |
| Polysaccharide 05 Ab.IgG5 (≥ 0.05 µg/ml) (POST) | 169 | 162 |
| Polysaccharide 05 Ab.IgG5 (≥ 0.2 µg/ml) (PRE) | 130 | 115 |
| Polysaccharide 05 Ab.IgG5 (≥ 0.2 µg/ml) (POST) | 163 | 155 |
| Polysaccharide 6B Ab.IgG (≥ 0.05 µg/ml) (PRE) | 158 | 149 |
| Polysaccharide 6B Ab.IgG (≥ 0.05 µg/ml) (POST) | 164 | 160 |
| Polysaccharide 6B Ab.IgG (≥ 0.2 µg/ml) (PRE) | 106 | 110 |
| Polysaccharide 6B Ab.IgG (≥ 0.2 µg/ml) (POST) | 157 | 147 |
| Polysaccharide 7F Ab.IgG (≥ 0.05 µg/ml) (PRE) | 159 | 154 |
| Polysaccharide 7F Ab.IgG (≥ 0.05 µg/ml) (POST) | 169 | 162 |
| Polysaccharide 7F Ab.IgG (≥ 0.2 µg/ml) (PRE) | 127 | 130 |
| Polysaccharide 7F Ab.IgG (≥ 0.2 µg/ml) (POST) | 165 | 161 |
| Polysaccharide 9V Ab.IgG (≥ 0.05 µg/ml) (PRE) | 165 | 150 |
| Polysaccharide 9V Ab.IgG (≥ 0.05 µg/ml) (POST) | 168 | 160 |
| Polysaccharide 9V Ab.IgG (≥ 0.2 µg/ml) (PRE) | 123 | 117 |
| Polysaccharide 9V Ab.IgG (≥ 0.2 µg/ml) (POST) | 166 | 157 |
| Polysaccharide 14 Ab.IgG (≥ 0.05 µg/ml) (PRE) | 170 | 163 |
| Polysaccharide 14 Ab.IgG (≥ 0.05 µg/ml) (POST) | 169 | 162 |
| Polysaccharide 14 Ab.IgG (≥ 0.2 µg/ml) (PRE) | 168 | 160 |
| Polysaccharide 14 Ab.IgG (≥ 0.2 µg/ml) (POST) | 168 | 162 |
| Polysaccharide 18C Ab.IgG (≥ 0.05 µg/ml) (PRE) | 166 | 161 |
| Polysaccharide 18C Ab.IgG (≥ 0.05 µg/ml) (POST) | 169 | 162 |
| Polysaccharide 18C Ab.IgG (≥ 0.2 µg/ml) (PRE) | 154 | 148 |
| Polysaccharide 18C Ab.IgG (≥ 0.2 µg/ml) (POST) | 168 | 159 |
| Polysaccharide 19A Ab.IgG (≥ 0.05 µg/ml) (PRE) | 168 | 160 |
| Polysaccharide 19A Ab.IgG (≥ 0.05 µg/ml) (POST) | 169 | 161 |
| Polysaccharide 19A Ab.IgG (≥ 0.2 µg/ml) (PRE) | 146 | 148 |
| Polysaccharide 19A Ab.IgG (≥ 0.2 µg/ml) (POST) | 165 | 158 |
| Polysaccharide 19F Ab.IgG (≥ 0.05 µg/ml) (PRE) | 169 | 160 |
| Polysaccharide 19F Ab.IgG (≥ 0.05 µg/ml) (POST) | 169 | 162 |
| Polysaccharide 19F Ab.IgG (≥ 0.2 µg/ml) (PRE) | 151 | 152 |
| Polysaccharide 19F Ab.IgG (≥ 0.2 µg/ml) (POST) | 169 | 161 |
| Polysaccharide 23F Ab.IgG (≥ 0.05 µg/ml) (PRE) | 151 | 151 |
| Polysaccharide 23F Ab.IgG (≥ 0.05 µg/ml) (POST) | 165 | 159 |
| Polysaccharide 23F Ab.IgG (≥ 0.2 µg/ml) (PRE) | 112 | 125 |
| Polysaccharide 23F Ab.IgG (≥ 0.2 µg/ml) (POST) | 155 | 147 |
Anti-pneumococcal antibody concentrations were expressed as adjusted geometric mean concentrations (GMCs) PRE = Pre -vaccination i.e. at Day 0 for Co-Ad Group and at Day 28 for Control Group. POST = Post-vaccination i.e. at Day 28 for Co-Ad Group and at Day 56 for Control Group.
| Titers | Control Group | Co-Ad Group |
|---|---|---|
| Polysaccharide 01 Ab.IgG (PRE) | 0.4 (0.3 to 0.5) | 0.4 (0.3 to 0.5) |
| Polysaccharide 01 Ab.IgG (POST) | 5.5 (4.3 to 7.0) | 4.9 (3.9 to 6.2) |
| Polysaccharide 03 Ab.IgG (PRE) | 0.4 (0.3 to 0.5) | 0.5 (0.4 to 0.6) |
| Polysaccharide 03 Ab.IgG (POST) | 1.7 (1.4 to 2.1) | 1.7 (1.4 to 2.0) |
| Polysaccharide 04 Ab.IgG (PRE) | 0.2 (0.2 to 0.3) | 0.2 (0.2 to 0.2) |
| Polysaccharide 04 Ab.IgG (POST) | 2.3 (1.8 to 2.9) | 1.7 (1.4 to 2.2) |
| Polysaccharide 05 Ab.IgG5 (PRE) | 0.6 (0.5 to 0.7) | 0.5 (0.4 to 0.6) |
| Polysaccharide 05 Ab.IgG5 (POST) | 7.8 (5.9 to 10.4) | 5.7 (4.3 to 7.5) |
| Polysaccharide 6B Ab.IgG (PRE) | 0.4 (0.3 to 0.6) | 0.4 (0.3 to 0.5) |
| Polysaccharide 6B Ab.IgG (POST) | 3.9 (2.9 to 5.1) | 3.1 (2.3 to 4.1) |
| Polysaccharide 7F Ab.IgG (PRE) | 0.6 (0.5 to 0.8) | 0.7 (0.6 to 0.9) |
| Polysaccharide 7F Ab.IgG (POST) | 9.0 (6.9 to 11.8) | 8.1 (6.2 to 10.6) |
| Polysaccharide 9V Ab.IgG (PRE) | 0.5 (0.4 to 0.7) | 0.5 (0.4 to 0.6) |
| Polysaccharide 9V Ab.IgG (POST) | 5.9 (4.8 to 7.4) | 4.4 (3.6 to 5.5) |
| Polysaccharide 14 Ab.IgG (PRE) | 3.7 (3.1 to 4.6) | 2.9 (2.4 to 3.5) |
| Polysaccharide 14 Ab.IgG (POST) | 20.2 (16.0 to 25.6) | 14.1 (11.3 to 17.6) |
| Polysaccharide 18C Ab.IgG (PRE) | 1.4 (1.1 to 1.7) | 1.2 (1.0 to 1.5) |
| Polysaccharide 18C Ab.IgG (POST) | 13.5 (10.7 to 16.8) | 11.1 (9.0 to 13.6) |
| Polysaccharide 19A Ab.IgG (PRE) | 1.3 (1.0 to 1.6) | 1.5 (1.2 to 1.9) |
| Polysaccharide 19A Ab.IgG (POST) | 9.2 (7.1 to 11.9) | 7.7 (6.1 to 9.8) |
| Polysaccharide 19F Ab.IgG (PRE) | 1.3 (1.1 to 1.7) | 1.4 (1.2 to 1.8) |
| Polysaccharide 19F Ab.IgG (POST) | 11.9 (9.3 to 15.2) | 10.6 (8.4 to 13.6) |
| Polysaccharide 23F Ab.IgG (PRE) | 0.4 (0.3 to 0.6) | 0.5 (0.4 to 0.7) |
| Polysaccharide 23F Ab.IgG (POST) | 3.1 (2.3 to 4.1) | 2.9 (2.2 to 3.8) |
Fold antibody concentration increases post-vaccination/pre-vaccination ≥ 2 and ≥ 4. The anti-pneumococcal serotypes assessed were 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.
| Subjects | Control Group | Co-Ad Group |
|---|---|---|
| Polysaccharide 01 Ab.IgG (≥ 2) | 149 | 144 |
| Polysaccharide 01 Ab.IgG (≥ 4) | 134 | 126 |
| Polysaccharide 03 Ab.IgG (≥ 2) | 121 | 97 |
| Polysaccharide 03 Ab.IgG (≥ 4) | 80 | 65 |
| Polysaccharide 04 Ab.IgG (≥ 2) | 149 | 137 |
| Polysaccharide 04 Ab.IgG (≥ 4) | 127 | 112 |
| Polysaccharide 05 Ab.IgG5 (≥ 2) | 156 | 138 |
| Polysaccharide 05 Ab.IgG5 (≥ 4) | 127 | 114 |
| Polysaccharide 14 Ab.IgG (≥ 2) | 123 | 102 |
| Polysaccharide 14 Ab.IgG (≥ 4) | 90 | 82 |
| Polysaccharide 18C Ab.IgG (≥ 2) | 149 | 133 |
| Polysaccharide 18C Ab.IgG (≥ 4) | 123 | 116 |
| Polysaccharide 19A Ab.IgG (≥ 2) | 133 | 123 |
| Polysaccharide 19A Ab.IgG (≥ 4) | 111 | 87 |
| Polysaccharide 19F Ab.IgG (≥ 2) | 146 | 141 |
| Polysaccharide 19F Ab.IgG (≥ 4) | 111 | 109 |
| Polysaccharide 23F Ab.IgG (≥ 2) | 133 | 122 |
| Polysaccharide 23F Ab.IgG (≥ 4) | 108 | 94 |
| Polysaccharide 6B Ab.IgG (≥ 2) | 141 | 127 |
| Polysaccharide 6B Ab.IgG (≥ 4) | 113 | 109 |
| Polysaccharide 7F Ab.IgG (≥ 2) | 155 | 144 |
| Polysaccharide 7F Ab.IgG (≥ 4) | 138 | 119 |
| Polysaccharide 9V Ab.IgG (≥ 2) | 146 | 140 |
| Polysaccharide 9V Ab.IgG (≥ 4) | 131 | 121 |
Collected over Serious Adverse Events: During the entire study period (Day 0 to 180); Solicited local and general symptoms: During the 7-day (Days 0-6) post-vaccination period; Unsolicited adverse events: During the 28-day (Days 0-27) post-vaccination period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Control Group | — | 11/179 (6.1%) | 117/179 (65.4%) |
| Co-Ad Group | — | 7/177 (4%) | 127/177 (71.8%) |
| Event | Control Group | Co-Ad Group |
|---|---|---|
| Coronary artery stenosisCardiac disorders | 2/179 | 0/177 |
| Angina pectorisCardiac disorders | 0/179 | 1/177 |
| Cardiac failureCardiac disorders | 0/179 | 1/177 |
| Cardio-respiratory arrestCardiac disorders | 0/179 | 1/177 |
| Intestinal malrotationCongenital, familial and genetic disorders | 0/179 | 1/177 |
| Intestinal ischaemiaGastrointestinal disorders | 0/179 | 1/177 |
| ErysipelasInfections and infestations | 0/179 | 1/177 |
| Wrist fractureInjury, poisoning and procedural complications | 0/179 | 1/177 |
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 0/179 | 1/177 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/179 | 1/177 |
| Event | Control Group | Co-Ad Group |
|---|---|---|
| PainGeneral disorders | 76/179 | 92/177 |
| FatigueGeneral disorders | 43/179 | 43/177 |
| MyalgiaMusculoskeletal and connective tissue disorders | 32/179 | 28/177 |
| HeadacheNervous system disorders | 31/179 | 27/177 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 25/179 | 25/177 |
| Gastrointestinal disorderGastrointestinal disorders | 23/179 | 17/177 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 16/179 | 19/177 |
| ChillsGeneral disorders | 13/179 | 14/177 |
| ErythemaSkin and subcutaneous tissue disorders | 13/179 | 10/177 |
| SwellingGeneral disorders | 6/179 | 9/177 |
| Age, Continuous(Years) | Control Group | Co-Ad Group | Total |
|---|---|---|---|
| Mean | 68.4 ± 9.4 | 68.1 ± 9.0 | 68.3 ± 9.2 |
| Sex: Female, Male(Participants) | Control Group | Co-Ad Group | Total |
|---|---|---|---|
| Female | 77 | 76 | 153 |
| Male | 102 | 101 | 203 |
| Race/Ethnicity, Customized(Participants) | Control Group | Co-Ad Group | Total |
|---|---|---|---|
| African Heritage / African American | 1 | 2 | 3 |
| White - Arabic / North African Heritage | 3 | 1 | 4 |
| White - Caucasian / European Heritage | 175 | 172 | 347 |
| Mixed Origin | 0 | 2 | 2 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Ran from Oct 2014 to primary completion in Jan 2015, 3 months.
Results were first posted in Mar 2017, 2 years 1 month after primary completion. A results delay was requested in Jan 2016.
Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 3 months is below that.
Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 23-valent pneumococcal capsular polysaccharide vaccine